Forgetfulness is a major contributor to nonadherence to chronic disease medications and could be addressed with medication reminder devices.
S uboptimal adherence to medications for chronic conditions, such as hypertension and diabetes, results in potentially avoidable morbidity, mortality, and health care spending.
1,2 A variety of factors are responsible for patients not taking their medications as prescribed, but up to 60% of individuals identify forgetfulness as their primary explanation. [1] [2] [3] Therefore, tools that remind patients to take their prescribed medications may help improve adherence by providing visual or auditory cues and by creating good habits around routine medication taking. [4] [5] [6] Particular attention has been focused on electronic medication-packaging devices that provide alerts when medications are to be taken as well as feedback to patients and their caregivers about adherence. Unfortunately, there are limited and inconsistent data supporting the effectiveness of these devices; in many cases, their cost may be prohibitive for wide-scale application.
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Simple and low-cost reminder devices, such as pill bottle caps with a digital timer or nonelectronic pillboxes, could be a cost-efficient alternative to overcoming forgetfulness. Small studies have found that such low-cost devices improve adherence to antiretroviral medications, but there are limited data about their ability to improve the quality of medication taking in other therapeutic areas, especially in real-world naturalistic settings. 5, 8, 9 Accordingly, we conducted the Randomized Evaluation to Measure Improvements in Nonadherence from Low-Cost Devices (REMIND) trial to evaluate the effect on adherence to medications for chronic conditions commonly managed in primary care settings of 3 low-cost devices: a pill bottle strip with toggles for each day of the week, a pill bottle cap with a digital timer displaying the time elapsed since the medication was last taken, and a plastic organization box with 1 compartment for every day of the week.
Methods

Study Design
The REMIND trial was a pragmatic, block-randomized, controlled, 4-arm comparative effectiveness study. Details of the study design and protocol have been published previously.
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The academic authors (N.K.C., N.F.K., A.A.K., A.Y.T., and J.M.F.) analyzed the data using an independent copy of the study database and attested to the analytic accuracy and completeness as well as the fidelity of the report to the trial protocol (available in Supplement 1). The trial was approved by the institutional review board of Brigham and Women's Hospital, Boston, Massachusetts, and by the Chesapeake Institutional Review Board. Because the study devices are currently available for commercial use and because participants received the devices by mail and could choose not to use them, patient-level consent was waived by Chesapeake Institutional Review Board.
Study Devices
The REMIND trial evaluated 3 low-cost adherence devices: (1) a pill bottle with an affixed strip with toggles that can be slid after each day's dose has been taken (Take-n-Slide; IC Innovations), (2) a pill bottle cap with a digital timer displaying the time elapsed since the medication was last taken (Rx TimerCap; TimerCap LLC), and (3) a standard plastic pillbox with 1 compartment for each day of the week (Appendix eFigure 1 in Supplement 2).
Study Population
In our study, conducted from February 12, 2013, through March 21, 2015, we enrolled individuals aged 18 to 64 years whose prescription drug benefits were administered by CVS Caremark, a large pharmacy benefits manager that provides coverage to more than 65 million individual members in the United States. We included only commercially insured individuals whose plan sponsor had provided permission to contact their members for this study and who were continuously eligible for pharmacy benefits in the 12 months before the start of the study. Thus, individuals aged 65 years or older, for whom Medicare is typically the primary payer and for whom accurate outcome data would not be available, were excluded.
Eligible patients were identified using prescription claims data. To be included, patients must have filled between 1 and 3 oral maintenance medications for the treatment of cardiovascular disease (ie, hypertension, hyperlipidemia, coronary artery disease, congestive heart failure, or diabetes), another nondepression chronic condition (ie, breast cancer; benign prostatic hypertrophy; schizophrenia, bipolar disorder, and anxiety; arrhythmia; Parkinson disease; or seizure and epilepsy); or depression in the 12 months before February 2014, when eligibility for the study was evaluated (see eTable 1 in Supplement 2 for the study medications and eFigure 2 in Supplement 2 for the study timeline). We restricted potentially eligible individuals to those taking 3 or fewer medications to limit the number of devices that patients with more complex treatment regimens may be required to use at any point ( Figure 1) .
In addition, to target individuals who may have been most likely to benefit from efforts to improve adherence, we required participants to have been suboptimally adherent to all of their qualifying oral maintenance medications during the 12 months prior to randomization. Adherence was assessed using prescription drug claims, and suboptimal adherence was defined as a medication possession ratio (MPR) between 30% and 80%. The 30% threshold was selected so that those patients in the cohort who normally filled more medications with every dispensation (eg, 90-day supply) would have filled at 11, 12 
Randomization and Study Procedures
Because antidepressants, unlike the other medication classes in this study, are generally not intended for lifelong use, we stratified participants prior to randomization on the basis of antidepressants being their only eligible medication ( Figure 1) . [13] [14] [15] As a result, stratum 1 (the chronic disease stratum) consisted of patients who took and were suboptimally adherent to up to 3 medications for cardiovascular or other nondepression chronic conditions. Stratum 2 (the antidepressant stratum) consisted of patients whose only qualifying medication was an antidepressant. Within each of the 2 strata, randomization occurred within blocks defined by whether all of the patient's targeted medications were dosed once daily. Patients with at least 1 medication dosed more than once daily (blocks B and D) were not eligible for the pill bottle strip with toggles, which can be used only for medications dosed once per day, and were randomized to 1 of 3 intervention arms. Within each block, randomization was carried out in a 2:1 ratio between each of the device and control arms. Patients who were randomized to one of the intervention arms received a free device in the mail along with an information card explaining how to use the device as well as whom and what telephone number to call to obtain additional information during the trial. Patients who were randomized to the pill bottle strip with toggles arm or the digital timer cap arm received 1 device for each targeted medication. Patients who were randomized to the standard pillbox arm received 1 device to use for all of their medications.
Study devices were mailed across 4 days in late March 2014 by US Postal Service first-class mail. Individuals randomized to the control arm were not contacted and did not receive any of the devices. Because the receipt dates for each patient are not precisely known, the last day of the mailing period was used as the start of follow-up for all participants. During the 6-week period between targeting and deploying the study devices, a small proportion of enrolled patients lost insurance eligibility and thus received the devices but could not be included in the analysis (Figure 1 ).
Study Outcomes
The study's primary outcome was a binary measure of optimal adherence during the 12-month follow-up period to all cardiovascular or nondepression chronic disease medications for participants in the chronic disease stratum. For each eligible medication, an MPR was first calculated using administrative pharmacy claims. Patients were defined as being optimally adherent if their MPR was equal to or greater than 80% for each and all of their eligible medications. Patients who lost insurance eligibility during follow-up were censored at their first eligibility gap of greater than 7 days, and outcomes were calculated over this truncated period.
Secondary outcomes were calculated in an analogous manner and included optimal adherence to cardiovascular medications among participants targeted for these medications in the chronic disease stratum 1 and optimal adherence to antidepressants in the antidepressant stratum. 
Statistical Analysis
We randomized 37 532 patients in the chronic disease stratum to achieve more than 80% power to detect a 1% difference in the percentage of patients who were optimally adherent between each of the individual intervention arms and controls as well as between each 2-way comparison of active arms, assuming that 2% of patients in the control group were optimally adherent, and an α of 5%. The randomization sequence was generated using PROC SURVEYSELECT with a fixed seed in SAS Enterprise Guide 5.1 (SAS Institute Inc). All analyses were performed on the basis of the intentionto-treat principle. We calculated means and frequencies of prerandomization variables separately by study arm. We also compared the average length of follow-up by study arm.
In the primary analyses, all outcomes were compared between study arms using standard logistic regression. We accounted for differences in level of optimal adherence for patients in each block by adjusting for block in the regression model. In a subsequent analysis, we compared outcomes between study arms using a generalized estimating equation with a logit link to account for clustering of participants within participating employers. We also evaluated adherence as a continuous measure, calculated as the average MPR across targeted medications, using linear regression. Finally, we conducted subgroup analyses of the primary outcome, stratifying our population by sex, age (<50 years vs ≥50 years), adherence level prior to randomization (MPR <0.55 vs ≥0.55), and number of targeted maintenance medications (between 1 and 3).
Results
Of the 53 480 potentially eligible participants, 1.5% to 2% of patients in each study arm lost insurance eligibility between targeting and deploying the devices. The final sample size for analysis was 36 739 in the chronic disease stratum and 15 555 in the antidepressant stratum. See Figure 1 for more information.
The baseline characteristics of the study participants are presented in Table 1 . In the entire cohort, mean (SD) age was 45 (12) years and 56% were females. Within study blocks, patients randomized to each of the treatment arms were well balanced and had similar lengths of follow-up. Compared with patients in the chronic disease stratum, patients in the antidepressant stratum were younger, more likely to be female, and less likely to live in neighborhoods with higher incomes and a greater proportion of individuals with white race/ethnicity.
In the chronic disease stratum, 15.1% of control patients became optimally adherent during follow-up compared with 15.5% of patients in the pillbox arm, 15.1% of patients in the digital timer cap arm, and 16.3% of patients in the pill bottle strip with toggles arm (Figure 2A) . In logistic models comparing study arms to controls and adjusted for study block, the odds of full adherence were not substantially different among the intervention arms or controls ( Table 2 ). In direct comparisons between devices, patients randomized to receive a pillbox had a statistically significant 10% higher odds of optimal adherence than those randomized to receive a pill bottle strip with toggles (odds ratio [OR], 1.10; 95% CI, 1.00-1.21). Analyses were similar when accounting for the clustering of patients within employers (OR, 1.10; 95% CI, 0.98-1.24; eTable 2inSupplement 2). Across subgroups, males with the pill bottle strip with toggles had substantially higher adherence than did females with the same device, and patients with higher levels of adherence before randomization responded better to the digital timer cap (OR, 1.07; 95% CI, 1.01-1.15) than did patients with lower prerandomization levels of adherence (OR, 0.96; 95% CI, 0.90-1.03; P value for interaction = .02). Effects across other subgroups, defined by sex and number of medications taken at randomization, were consistent ( Table 3) .
Analyses of secondary outcomes were consistent with those of the primary outcome (Table 2 and Figure 2B and C). None of the devices differed substantially from the control arm with respect to optimal adherence to cardiovascular medications or antidepressants. In direct comparisons, patients randomized to the pillbox arm had a 14% higher odds of optimal adherence to antidepressants than patients randomized to the digital timer cap arm (OR, 1.14; 95% CI, 1.02-1.29; Table 2 ). Analyses considering adherence as a continuous outcome calculated as the mean MPR across eligible medications also yielded similar results (eTable 3 in Supplement 2).
Discussion
In this pragmatic, comparative-effectiveness randomized clinical trial of more than 50 000 individuals who took up to 3 longterm medications to treat chronic conditions but were nonadherent to these therapies, 3 low-cost devices-pill bottle strip with toggles, digital timer cap, and standard pillbox-did not improve medication adherence. In head-to-head comparisons of individual devices, patients who received the standard pillbox tended to have higher adherence than patients who received the digital timer cap and the pill bottle strip with toggles, although these effects were of relatively small magnitude and were of inconsistent statistical significance.
There are several potential explanations for our null findings. First, we selected for inclusion those patients who had suboptimal adherence and then we anticipated that, during our yearlong follow-up, 2% of our controls would become optimally adherent. In contrast, we observed that 12% to 18% of controls actually became optimally adherent without specific intervention. This finding is consistent with recent observations that adherence, like other health behaviors, is dynamic, with a sizable proportion of previously nonadherent patients demonstrating periods of adherence and vice versa. 16, 17 As such, it may have been preferable to instead target patients who were predicted to be nonadherent in the future (by using recently described methods, for example) rather than target those who were nonadherent at the point of randomization.
18,19
Second, in an intention-to-treat framework, low uptake or inconsistent use could have obscured any true effects among those who used the devices regularly. Our study was powered to detect a 1% mean improvement in the rate of optimal adherence under the assumption that approximately 20% of patients in the intervention arms would use the devices. In a survey of 618 patients randomized to one of the intervention arms conducted in the third month of follow-up, more than 68% reported using the devices. However, given the overall null results of the intervention, such use either was not sustained in the yearlong follow-up or did not lead to measurable changes in the rate of filling. In some cases, patients may not have used the devices as intended; although an information card accompanied the devices, 40% of those surveyed either did not read the card or found it unhelpful. For patients randomized to the digital timer cap arm, we used pharmacy data to predict which size cap would fit over patients' existing pill bottles; however, size discrepan- Percentage of patients optimally adherent in the chronic disease stratum (A), in the chronic disease stratum and targeted for a cardiovascular medication (B), and in the antidepressant stratum (C). CVD indicates cardiovascular disease.
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Effect of Reminder Devices on Medication Adherence cies could have prevented some patients from using the timer cap device. Those surveyed frequently reported difficulties with putting on and taking off the digital timer cap device. The fact that the standard pillbox, ubiquitous in pharmacies and other care settings, resulted in marginally greater improvements in adherence than the other two devices may suggest that familiarity and comfort with a device could have facilitated uptake and the resultant behavior change. Third, to be pragmatic, the mailing of devices was not coordinated with actual medication refills. Thus, patients may have had difficulty transitioning to the device in the middle of a prescription fill. Or patients may have not used the devices at all if their medication refill had lapsed completely, leaving them without medication to put in the device at the time it was received.
Another possible explanation for our findings is that these devices simply do not improve adherence. These 3 devices are simple by design, intended to be intuitive to use, and minimally disruptive. However, for patients without established routines around medication taking, the additional cues from these devices may not be sufficient to overcome forgetfulness. Moreover, the devices may not have promoted periodic medication refilling, which is necessary for long-term adherence. For these devices to work, they may need to be administered with additional support mechanisms.
Alternatively, although forgetfulness is the most frequent barrier to adherence that patients report, this factor may not have been the primary driver of nonadherence in our study population. For example, a common theme in the patient survey for the trial participants was a belief that adherence was not a problem for them, suggesting that gaps in knowledge or motivation could have been the primary contributors to suboptimal medication taking. Similarly, because nonadherence is a multidimensional problem, addressing forgetfulness alone may have been insufficient to improve actual medication taking. This idea is consistent with the modest effects seen in other studies that address single barriers, such as high outof-pocket medication costs. 20 Conversely, multicomponent interventions, particularly those led by pharmacists, appear to be effective. Trials are now being conducted to test ways to increase the efficiency of pharmacy-patient interactions, including delivering pharmacy services by telephone and linking these services to other resources, such as text messages and performance reports drawn from routinely collected administrative claims and electronic health record data.
21,22
Limitations
This study has several limitations. Our multiarm study design necessitated making multiple comparisons and conducting several hypothesis tests. Thus, the few statistically significant findings reported here could be the result of chance. A small proportion of patients lost insurance eligibility before the devices were mailed, and another set of patients lost eligibility during follow-up. We did not observe substantial differences in the loss-to-follow-up rate between study arms because much of this loss to follow-up can be attributed to normal insurance churn. A higher-than-anticipated proportion of control patients were observed to be adherent during followup; however, given that almost no effect was observed across any comparisons in our study, we do not believe the interpretation of our results would change. Targeting for the trial and the outcomes were evaluated using medication dispensing data. Such data sources have been demonstrated to be valid and accurate measures of medication-taking behavior, 23 but some misclassification of actual use could have occurred if patients stopped taking their medications midway through a fill. Similarly, claims data do not allow for the differentiation of patients who are intermittent users from patients who have discontinued therapy altogether. Such misclassification could undermine our measurement of the effectiveness of these devices in improving adherence. Given the minimal impact of these devices in improving rates of medication filling, we do not expect the devices to have differentially caused patients to stop taking their medications midway through a fill.
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Included in our list of targeted medications were anxiolytics. Although these drugs are used by many patients for long periods, they are not intended for lifelong use. For very few patients, an anxiety medication was the only drug that qualified them for inclusion in the chronic disease stratum; we found this to be reassuring, and our results were virtually identical in our prespecified analysis restricted to cardiovascular medications. Our trial population consisted of patients who were continuously enrolled in a commercial pharmacy benefits manager for 12 to 24 months and who were taking between 1 and 3 maintenance medications. Some of these patients may have been simultaneously enrolled in an autorefill program; however, we expect the distribution of enrolled patients to be balanced by design. Finally, our results may not be fully generalizable to older and/or Medicare-insured populations and to those with greater medication maintenance complexity. 24 
Conclusions
In a large, pragmatic, comparative-effectiveness randomized clinical trial of patients across a broad range of chronic conditions, low-cost devices did not measurably improve medication adherence. Future research should focus on effective strategies to ensure uptake and sustained use of these interventions. Using pill counts, the investigators discovered that about half of the workers were taking less than 80% of their blood pressure pills and that the nonadherent workers were less likely to have controlled blood pressure. In the subsequent 40 years, the amount of research dedicated to medication nonadherence increased exponentially (Figure) . Health economists have identified medication adherence interventions as opportunities for improving health outcomes while reducing health care costs. Stakeholders ranging from the Agency for Healthcare Research and Quality to the World Health Organization issued calls to action for the implementation of strategies to improve medication adherence. Despite this increased attention, the prevalence of medication nonadherence is as high as ever, and up to 50% of patients remain nonadherent to treatments prescribed for chronic health conditions.
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In this issue of JAMA Internal Medicine, Choudhry and colleagues 3 describe an elegant experiment testing a low-cost, scalable solution to improving medication adherence. Specifically, they compare the effect of providing commercially insured patients who were nonadherent to chronic disease medications with usual care vs with 1 of 3 reminder devices-a standard pillbox, a toggle strip that can indicate whether a daily dose was taken, or a pill cap with a digital timer to indicate the time elapsed since last opening. The authors target forgetfulness, a major reason for nonadherence, and hypothesize that providing reminder devices would improve adherence. Influencing adherence through simple, easy-to-implement, and affordable interventions offers intriguing potential as a public health approach to solving this irascible problem. Unfortunately, the authors found that providing patients with these devices alone was not the answer to nonadherence. None of the 3 devices was superior to usual care at improving refill rates. The authors are commended for using a pragmatic trial to definitively test the effectiveness of these low-cost reminder devices. Nevertheless, the trial was not without its limitations. First, the authors evaluated the effect of the intervention on refill patterns but were unable to assess its effect on day-to-day adherence behavior; the reminder devices could have improved correct daily dosing (eg, reducing double dosing) without influencing refill rates. Second, the trial excluded elderly patients, who While these products have intuitive appeal and a number of them are commercially available, their ability to improve adherence remains unknown. Further, standard pillboxes are also inexpensive and have been used for decades, and the comparative effectiveness of these alternative products has not been evaluated. 
Research Goal and Objectives
The objective of this study is to determine whether adherence to oral maintenance medications differ for patients who are randomized to receive a Take-N-Slide, a RxTimer Cap, a pillbox, or none of these devices. Because care recommendations and treatment durations for depression differ from other chronic conditions, the primary outcome will evaluate adherence among patients sub-optimally adherent to targeted medications excluding antidepressants. Figure 1 illustrates the overall study design
Overall Design
Figure 1: Study Design
This study is a prospective, intent-to-treat, randomized control trial that will evaluate the impact of the three devices on medication adherence. Randomization will we stratified based upon which medications subjects had filled prior to randomization: (1) cardiovascular or other chronic disease medications or (2) an antidepressant. Within these strata, all patients meeting the inclusion criteria described below will be randomized in two blocks based upon the number of times per day filled medications were intended to be taking.
Patient Inclusion and Exclusion Criteria
The eligible member pool will consist of patients whose prescription drug benefits are administered by CVS Caremark, whose plan sponsor (i.e. the entity that provides the individual with insurance benefits) is a commercial plan, and whose sponsor has provided CVS Caremark with permission to contact their members with regard to this study.
Specific inclusion criteria are: §! 18 to 64 years of age at the time of identification for study eligibility; §! Have 1 to 3 oral maintenance medications with at least one medication intended to a chronic condition (defined as hypertension; hyperlipidemia; coronary artery disease;
congestive heart failure; diabetes; breast cancer; benign prostatic hypertrophy; schizophrenia, bipolar disorder, anxiety; Parkinson's disease; seizure and epilepsy) or depression that has been filled via mail order or at a retail pharmacy within 150 days prior to being identified as being eligible for the study; §! Poorly adherent to at least one targeted drug class a member is taking, defined as MPR or 30%-80% in at least one targeted drug class a member is taking during the 12 months preceding identification of study eligibility; §! For patients taking antidepressants in addition to other targeted medications, patients need only be poorly adherent to their non-antidepressant medications; §! Eligible for pharmacy benefits during the 12 months prior to being identified as being eligible for the study and expected to be eligible for pharmacy benefits through the end of the evaluation period Specific exclusion criteria are: §! Not enrolled in Ready Fill at Mail (a pharmacy benefit program whereby members elect to have medications shipped automatically to them at the time of refill due date or prescription renewal).
These criteria will be evaluated using routinely collected administrative pharmacy claims data.
Randomization
All members meeting the inclusion and exclusion criteria will be enrolled in the study (see below got consent) stratified based on the frequency with which their medications are (or could possibly be) taken.
Individuals whose medications are all intended for once daily use (Blocks A and C) will be randomized in a 1:2:2:2 ratio to one of the following four groups:
(1) Control group: usual care; Because the Take-N-Slide only has a yes/no toggle for each day of the week, patients who are on a medication that is or could be used more than once per day (Blocks B and D), will be randomized in a 1:2:2 ratio to one of the following three groups:
(1) Control group: usual care;
(2) Intervention 1: PillMinder;
(3) Intervention 2: Rx Timer Cap.
Randomization will be carried out using a random number generator. More patients will be randomized to the intervention than the control groups to maximize our ability to detect differences between the devices (see Sample Size Estimations, below). Once a member is assigned to a study group, s/he will remain assigned into the given arm for the duration of the study.
Study Devices (Appendix A)
The Take-N-Slide can be affixed onto any pill bottle. The patented strip has toggles for each day of the week which are meant to be slid after taking a medication. The device is intended to provide visual cues to remind patients if they have forgotten to take their medication and may also reduce "double dosing" patient errors. Each Take-N-Slide can be removed and reused for the next prescription bottle.
The RxTimerCap is a pill bottle with a digital timer on the cap that shows the time elapsed since the medication was last taken. The cap works like a stopwatch, automatically resetting the timer after the cap has been opened. Patients can immediately see when the last dosage was taken in order to prevent unnecessary or missed dosing.
The pillbox is a plastic organization box with one compartment for every day of the week.
Study Procedures
Patients randomized to one of the devices will receive a one-time mailing with the appropriate device(s) along with an information card explaining its use. Patients will receive a device for each of the maintenance medications when they were using at the time of identification for study eligibility. For example, a patient on 3 maintenance medications randomized to the RxTimer Cap arm will receive 3 RxTimer Caps. If patients have questions about their devices, the information card that arrives with it will provide a dedicated CVS Caremark telephone number at which they can get additional information. Patients will receive no other study-specific communication nor will they receive additional devices during follow-up. Controls will not receive a device and will not be contacted.
As a quality control measure, a subset of 600 intervention group participants will be surveyed via telephone or, upon follow-up, email regarding the delivery, function, and satisfaction of the devices. Survey participants will be randomly selected at 2 weeks, 3 months, and 6 months following product shipment.
Outcomes and Analysis
(a)! Outcomes
The primary study outcome will be optimal adherence to all cardiovascular or non-depression chronic disease medications (defined in Patient Inclusion and Exclusion Criteria above) over the 12-month period beginning from the date of randomization in Stratum 1. This outcome will be assessed using highly standard methods applied to administrative pharmacy claims that are routinely collected as part of CVS Caremark's business practices.
3 Optimal adherence will be defined as a Medication Possession Ratio (MPR) equal to or greater than 0.80. MPR is the ratio of the total number of days on which the participant had medications available (numerator) and the total number of possible days the participant could have had the medication on hand (denominator). The denominator is the total number of days within the measurement period (12 months), and is therefore the same for all participants. MPR will be calculated for each maintenance medication identified at the start of the study and patients will be defined as optimally adherent if their MPR is equal to or greater than 0.80 for each of their therapies.
Secondary outcomes will assess (a) optimal adherence to antidepressants among patients whose only targeted therapy is an antidepressant (i.e. patients in Stratum 2); (b) optimal adherence to the targeted therapies in each study block (A through D), independently; (c) optimal adherence to cardiovascular medications among patients who are poorly adherent to these medications at the time of randomization (i.e. a subset of patients in blocks A and B).
Tertiary outcomes will evaluate adherence as a continuous measure. In this case, adherence will be assessed based upon the mean MPR of all medications considered for that outcome.
(b) Analysis Plan
All analyses will be conducted based on intention-to-treat principles. The baseline characteristics of patients will be compared with t-tests and chi square tests, and their nonparametric analogues, as appropriate.
The primary (optimal adherence in Stratum 1) and secondary (optimal adherence in Stratum 2, optimal adherence to cardiovascular medications and optimal adherence in each study block independently) outcomes will be compared between study arms using standard logistic regression, adjusting for study block in the regression model.
In supplemental analyses, all outcomes will be compared between study arms using a generalized estimating equation (GEE) with a logit or linear link, depending on the outcome, to account for clustering of subjects within plan sponsors and will be adjusted for any differences in baseline characteristics between study groups that are believed, through analytical assessment and subject-matter expertise, to be confounders of the intervention-outcome association.
Sample Size Estimations
For the primary outcome, using a randomization ratio of 1:2 between control and each intervention arm and assuming a rate of optimal adherence of 2% in the control group, we will have 80% power with an alpha of 5% to detect a 1% difference in the rate of optimal adherence between intervention and control and among each of the intervention arms with 3,050 in control and 6,100 in each intervention arm, for a total of 21,350 and 15,250 in Block A and Block B, respectively. The assumption of a 2% adherence improvement in the control arm is based on the observation that adherence is dynamic, and thus that some patients in this population of subjects poorly-adherent at baseline will become optimally adherent during follow-up. 45 Under the assumption that approximately 20% of patients in intervention arms would use the devices, a 1% adherence improvement relative to control translates into a 7% improvement in the rate of optimal adherence among those intervened upon. Improvements of this magnitude have been observed in other adherence-improvement interventions and are believed to be clinically meaningful.
Pilot data collected in January 2014 indicated that 22,197 and 15,410 subjects would be eligible for Blocks A and C, and Blocks B and D, respectively.
Recruitment and Informed Consent
Because of the extremely low risk nature of this study and the study devices being tested, all of which are currently available for commercial use and the fact that patients will receive these devices via mail and may choose not to use them, no patient-level consent will be sought.
Further, given the size and nature of the study obtaining formal informed consent will be impractical and will substantially reduce the statistical power of the study as well as limit its generalizability to a small subset of individuals to whom it might ultimately be applied.
If patients have questions about their devices, the information card that arrives with it will provide a dedicated CVS Caremark telephone number at which they can get additional information (Appendix B).
Study Risks, Safety, Monitoring
Each intervention device presents minimal known additional risk to members. Each of the intervention devices is intended to supplement in adherence to medications that have been prescribed by their treating physicians and are filled at a pharmacy (mail-order or retail) of their choosing. The devices will not prevent the member from accessing his/her medications.
Included in the introductory study participation materials will be contact information should the member have any questions or concerns regarding the study or intervention devices.
Updates to original research protocol from 01/02/2014
Several minor changes were made to the trial design after the original trial protocol was finalized. The published trial protocol contains these changes (Contemporary Clinical Trials 2015; 43: 53-59). The specific modifications are summarized below:
1.! The randomization ratios were changed from 1:1.3 for control to each intervention arm to 1:2 to optimize statistical power based upon pilot data of the number of potentially eligible subjects.
2.! A survey of 600 intervention group participants regarding the delivery, function, and satisfaction of the devices was added as a quality control measure. To clarify this approach while keeping the pre-specified primary outcome unchanged, the description of the study was changed to consider it as single trial with 2 strata based upon the types of medication patients had filled at baseline and blocks based upon dosing frequency. The primary outcome remained unchanged (now clarified as being optimal adherence in Stratum 1 [previously Block A in Trial 1 and Block C in Trial 2]).
Adherence in Stratum 2 (antidepressant medication only) was redefined as a secondary outcome. Additional secondary outcomes (optimal adherence in each of the study blocks independently and optimal adherence to cardiovascular medications) were added. Mean adherence was changed from a secondary to a tertiary outcome. 
